€25.3m market cap
€1.23 last close
ASIT biotech is a clinical-stage company focused on developing therapies for allergies. It uses its proprietary ASIT+ technology platform to develop products containing highly purified allergen fragments in an adjuvant-free formulation, selected to be safe while maintaining the capacity to stimulate the immune system.
Investment summary
In this interview Michel Baijot, CEO of Asit Biotech, discusses what is unique about the company and what newsflow investors can expect from ASIT in the second half of 2019.
Y/E Dec |
Revenue (€m) |
EBITDA (€m) |
PBT (€m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 0.0 | (12.0) | (12.0) | (93.6) | N/A | N/A |
| 2018A | 0.0 | (12.8) | (14.3) | (85.7) | N/A | N/A |
| 2019E | 0.0 | (9.9) | (9.7) | (48.1) | N/A | N/A |
| 2020E | 0.0 | (5.3) | (5.5) | (19.1) | N/A | N/A |
| Last updated on 25/07/2019 | ||||||
Industry outlook
Although grass pollen and house dust mite allergies are not life-threatening in most cases, they result in a significant symptom burden for affected patients. With a safe and effective short-course pre-seasonal regimen, ASIT could expect some usage in patients accepting immunotherapy and the 50% of patients who refuse the existing almost year-round immunotherapy.
Last updated on 25/07/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (€m) | N/A |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Michel Baijot | CEO |
| Yves Desiront | CFO |
| Philippe Ghem | Chief Commercial Officer |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- Mologen
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- Selvita
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma